News

On September 26, 2024, TASS hosted an expert discussion in the format of a federal teleconference Moscow-St. Petersburg-Ekaterinburg-Novosibirsk-Vologda-Anapa, dedicated to discussing the role, reasons and mechanisms for stimulating In Ekaterinburg, Alexander Petrov, the Chairman of the Board of Directors of Medsintez Plant LLC, told the participants about Triazavirin, an innovative domestic antiviral drug, as a success case of private investment in science.

60 leading Russian reproductologists visited the pharmaceutical company Medsintez Plant in Novouralsk on September 4, 2024. This event was timed to coincide with the celebration of the 3rd anniversary of the opening of the production workshop for biotechnological substances for the reproductive health of women, as well as the Annual International Conference «Reproductive Technologies Today and Tomorrow» in Ekaterinburg. Leading experts and conference speakers visited the production of the first Russian follitropin alpha for the treatment of human infertility, Primapur®.

In 2024, the Medsintez Plant in collaboration with Tonghua Anrate Biopharmaceutical Co. launched the production of the substance and finished dosage forms of the world's first registered drug of recombinant human albumin. The drug was obtained using Pichia Pastoris cells by the recombinant DNA technology.

The Medsintez Plant has participated in an international business meeting with the delegation from the United Arab Emirates as part of the INNOPROM 2024 business program in Ekaterinburg. The meeting with representatives of the national Ministry of Industry, pharmaceutical and medical industries of the UAE was organized by the Ministry of Industry and Trade of the Russian Federation. The meeting was attended by the Deputy Minister of Industry and Advanced Technology of the UAE, representatives of Globalpharma, SayGen, Hayat Biotech, Abu Dhabi Medical Devices.

A meeting of the Committee on Entrepreneurship in Healthcare and Medical Industry of the Ural Chamber of Commerce and Industry was held on July 3, 2024, chaired by Alexander Petrov. The meeting was dedicated to the relationship between the labour productivity and the modification of risk factors in medical institutions of the Sverdlovsk Region, as well as the issues of government procurement of medical products and medicines from domestic manufacturers.

The 5th (XXX) National Congress of Endocrinologists «Innovative Technologies in Endocrinology» with international participation was held in Moscow from May 21 to 24, 2024, organized by the Russian Association of Endocrinologists and National Medical Research Center for Endocrinology, Federal State Budgetary Institution of the Russian Ministry of Health. Among the leading domestic and foreign pharmaceutical manufacturers, the Medsintez Plant presented its key products at the booth—genetically engineered and analogue human insulins Rosinsulin. Medical specialists who visited the exhibition expressed gratitude to the company for the affordability and high quality of its products.

On May 16, 2024, at the RUSSIA EXPO International Exhibition and Forum at the National Economy Achievements Exhibition site (VDNKh), a theme day Modern Health Saving Technologies was held, where enterprises participating in the Ural Biomedical Cluster presented their products at the joint booth of the Sverdlovsk Region. The exhibition was visited by Olga Krivonos, the Deputy Chief of the Russian Federation Government Office, and Mikhail Murashko, the Minister of Health of the Russian Federation. All regions, federal ministries, corporations and public organizations took part in the exhibition, representing the achievements of modern Russia.

Residents of the Ural Biomedical Cluster traditionally took part in the 5th international specialized exhibition-forum Healthcare of the Urals-2024, which took place from April 16 to 19 at the Ekaterinburg-Expo IEC. The event was attended by 160 manufacturers and suppliers of medical products from 34 cities of Russia, presenting over a thousand units of modern medical equipment, consumables, digital technologies for healthcare, services and components for medical equipment.

At the end of the last year, Novouralsk-based Medsintez Plant turned 20 years old. Alexander Petrov, Chairman of the plant's Board of Directors, told Regions of Russia about the impressive successes that the company has achieved over the years and its ambitious plans for the future.

In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease. The preparations are available in the most convenient and familiar for patients dosage form – a disposable prefilled injection and have already been supplied to pharmacies.